A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
This study is testing a targeted cancer medicine called Abemaciclib to see how well it works on advanced solid tumors that are not in the breast. It aims to help patients whose tumors have specific gene changes and who have already tried standard treatments.
You may be able to join if you are 18 or older, have an advanced non-breast solid tumor with specific genetic changes, and have not previously taken this type of drug. Your past treatments must also be finished and you must have recovered from their side effects.
Participants will receive the study medication, Abemaciclib, which is designed to block specific proteins and stop cancer cells from multiplying. Your health and tumor size will be closely monitored through regular check-ups and scans.
This study is currently recruiting participants in Boston, Massachusetts, United States. It is a Phase 2 trial looking closely at the safety and effectiveness of the treatment.
- 1Tests the targeted medication Abemaciclib for advanced solid tumors
- 2Requires specific genetic changes in your tumor identified through lab testing
- 3Currently recruiting patients in Boston, Massachusetts
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.